Study on Hold
Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold
Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; FDA; patient death; capillary leak syndrome; acute systemic infection; RP-A501; adverse event
FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme
United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO
FDA frees Amgen’s phase 1 obesity asset from clinical trial hold
Obesity, United States Food and Drug Administration, Amgen, MariTide, Study on Hold, Participant
Entrada tightens focus on Duchenne, axes 20% of staff
Duchenne muscular dystrophy (DMD), workforce reduction, ENTR-601-44, ENTR-601-45, FDA clinical hold, exon skipping therapy
FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns
Vyne, United States Food and Drug Administration, Testiculo-, Toxicity aspects, Study on Hold, United States Food and Drug Administration
FDA puts BioNTechs malaria vaccine on clinical hold
United States Food and Drug Administration, Malaria, Study on Hold, Vaccines, BioNTech ‘s, Clinical Trials
FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny
BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges
Atara Biotherapeutics Halves Workforce Amid FDA Setbacks for Key Therapies
Atara Biotherapeutics, layoffs, FDA clinical hold, Ebvallo, ATA3219, manufacturing issues
FDA Lifts Clinical Hold on Entrada’s Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years
Duchenne muscular dystrophy, ENTR-601-44, Entrada Therapeutics, FDA, clinical hold, exon 44 skipping, ELEVATE-44-102, Phase 1b trial
FDA Halts Amgen’s Phase 1 Obesity Drug Trial: AMG 513 Study on Hold
Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback